Trial Outcomes & Findings for Trial to Assess the Safety and Effects of Vorapaxar in Japanese Subjects With Acute Coronary Syndrome (P04772; MK-5348-016) (NCT NCT00684203)

NCT ID: NCT00684203

Last Updated: 2017-05-05

Results Overview

Recruitment status

COMPLETED

Study phase

PHASE2

Target enrollment

120 participants

Primary outcome timeframe

Up to Day 60

Results posted on

2017-05-05

Participant Flow

Of 120 participants enrolled and randomized to treatment, 117 participants were treated with study drug. 92 participants underwent percutaneous coronary intervention (PCI) and 25 did not.

Participant milestones

Participant milestones
Measure	Vorapaxar 20 mg (PCI) Vorapaxar 20 mg as loading dose is administered to PCI participants as the initial dose. From Day 2, 1 mg or 2.5 mg once daily is administered as the maintenance dose for 59 days (total duration of 60 days).	Vorapaxar 40 mg (PCI) Vorapaxar 40 mg as loading dose is administered to PCI participants as the initial dose. From Day 2, 1 mg or 2.5 mg once daily is administered as the maintenance dose for 59 days (total duration of 60 days).	Placebo/Placebo (PCI) Placebo as loading dose is administered as the initial dose to PCI participants. From Day 2, placebo once daily is administered as the maintenance dose for 59 days (total duration of 60 days).	Vorapaxar 20 mg (Non-PCI) Vorapaxar 20 mg as a loading dose is administered to non-PCI participants as the initial dose. From Day 2, 1 mg or 2.5 mg once daily is administered as the maintenance dose for 59 days (total duration 60 days).	Vorapaxar 40 mg (Non-PCI) Vorapaxar 40 mg as loading dose is administered to non-PCI participants as the initial dose. From Day 2, 1 mg or 2.5 mg once daily is administered as the maintenance dose for 59 days (total duration of 60 days).	Placebo/Placebo (Non-PCI) Placebo as loading dose is administered as the initial dose to non-PCI participants. From Day 2, placebo once daily is administered as the maintenance dose for 59 days (total duration of 60 days).
Overall Study STARTED	40	31	21	6	17	2
Overall Study COMPLETED	31	23	12	6	17	2
Overall Study NOT COMPLETED	9	8	9	0	0	0

Reasons for withdrawal

Reasons for withdrawal
Measure	Vorapaxar 20 mg (PCI) Vorapaxar 20 mg as loading dose is administered to PCI participants as the initial dose. From Day 2, 1 mg or 2.5 mg once daily is administered as the maintenance dose for 59 days (total duration of 60 days).	Vorapaxar 40 mg (PCI) Vorapaxar 40 mg as loading dose is administered to PCI participants as the initial dose. From Day 2, 1 mg or 2.5 mg once daily is administered as the maintenance dose for 59 days (total duration of 60 days).	Placebo/Placebo (PCI) Placebo as loading dose is administered as the initial dose to PCI participants. From Day 2, placebo once daily is administered as the maintenance dose for 59 days (total duration of 60 days).
Overall Study Adverse Event	6	4	8
Overall Study Protocol-defined clinical event	3	1	0
Overall Study Withdrawal by Subject	0	2	1
Overall Study Did not meet protocol eligibility	0	1	0

Baseline Characteristics

Trial to Assess the Safety and Effects of Vorapaxar in Japanese Subjects With Acute Coronary Syndrome (P04772; MK-5348-016)

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Vorapaxar 20 mg (PCI) n=40 Participants Vorapaxar 20 mg as loading dose is administered to PCI participants as the initial dose. From Day 2, 1 mg or 2.5 mg once daily is administered as the maintenance dose for 59 days (total duration of 60 days).	Vorapaxar 40 mg (PCI) n=31 Participants Vorapaxar 40 mg as loading dose is administered to PCI participants as the initial dose. From Day 2, 1 mg or 2.5 mg once daily is administered as the maintenance dose for 59 days (total duration of 60 days).	Placebo/Placebo (PCI) n=21 Participants Placebo as loading dose is administered as the initial dose to PCI participants. From Day 2, placebo once daily is administered as the maintenance dose for 59 days (total duration of 60 days).	Vorapaxar 20 mg (Non-PCI) n=6 Participants Vorapaxar 20 mg as a loading dose is administered to non-PCI participants as the initial dose. From Day 2, 1 mg or 2.5 mg once daily is administered as the maintenance dose for 59 days (total duration 60 days).	Vorapaxar 40 mg (Non-PCI) n=17 Participants Vorapaxar 40 mg as loading dose is administered to non-PCI participants as the initial dose. From Day 2, 1 mg or 2.5 mg once daily is administered as the maintenance dose for 59 days (total duration of 60 days).	Placebo/Placebo (Non-PCI) n=2 Participants Placebo as loading dose is administered as the initial dose to non-PCI participants. From Day 2, placebo once daily is administered as the maintenance dose for 59 days (total duration of 60 days).	Total n=117 Participants Total of all reporting groups
Age, Continuous	64.3 Years STANDARD_DEVIATION 9.2 • n=5 Participants	64.5 Years STANDARD_DEVIATION 9.0 • n=7 Participants	65.0 Years STANDARD_DEVIATION 10.8 • n=5 Participants	59.0 Years STANDARD_DEVIATION 14.3 • n=4 Participants	64.1 Years STANDARD_DEVIATION 13.6 • n=21 Participants	66.5 Years STANDARD_DEVIATION 3.5 • n=8 Participants	64.2 Years STANDARD_DEVIATION 10.3 • n=8 Participants
Sex: Female, Male Female	5 Participants n=5 Participants	9 Participants n=7 Participants	5 Participants n=5 Participants	0 Participants n=4 Participants	9 Participants n=21 Participants	1 Participants n=8 Participants	29 Participants n=8 Participants
Sex: Female, Male Male	35 Participants n=5 Participants	22 Participants n=7 Participants	16 Participants n=5 Participants	6 Participants n=4 Participants	8 Participants n=21 Participants	1 Participants n=8 Participants	88 Participants n=8 Participants

PRIMARY outcome

Timeframe: Up to Day 60

Population: The population included all enrolled participants who received at least 1 dose of study drug and underwent PCI.

Outcome measures

Outcome measures
Measure	Vorapaxar 20 mg Loading Dose PCI n=40 Participants Vorapaxar 20 mg as a loading dose is administered as the initial dose. From Day 2, 1mg or 2.5 mg once daily is administered as the maintenance dose for 59 days (total duration of 60 days).	Vorapaxar 40 mg Loading Dose PCI n=31 Participants Vorapaxar 40 mg as a loading dose is administered as the initial dose. From Day 2, 1 mg or 2.5 mg once daily is administered as the maintenance dose for 59 days (total duration of 60 days).	Placebo/Placebo PCI n=21 Participants Placebo as loading dose is administered as the initial dose. From Day 2, placebo once daily is administered as the maintenance dose for 59 days (total duration of 60 days).	Vorapaxar 40 mg/2.5 mg PCI Vorapaxar 40 mg as loading dose is administered as the initial dose. From Day 2, 2.5 mg once daily is administered as the maintenance dose for 59 days (total duration of 60 days).	Placebo/Placebo PCI Placebo as loading dose is administered as the initial dose. From Day 2, placebo once daily is administered as the maintenance dose for 59 days (total duration of 60 days).
Number of Participants Experiencing Adverse Events (AEs) Who Underwent Percutaneous Coronary Interventions (PCI)	40 Participants	30 Participants	21 Participants	—	—

SECONDARY outcome

Timeframe: Up to Day 121

Population: The population included all enrolled participants who received at least 1 dose of study drug and underwent PCI with Non-Major MACE data available.

An AE is any unfavorable and unintended change in the structure, function or chemistry of the body temporally associated with study drug administration, whether or not considered related to the study drug. MACE events were defined as nonfatal myocardial infarction (MI), nonfatal stroke, hospitalization due to recurrent ischemia, or urgent coronary revascularization performed ≥ 30 days after administration of the loading dose (Day 1). All MACE events were excluded from this analysis. Analysis of data was by loading/maintenance dose group.

Outcome measures

Outcome measures
Measure	Vorapaxar 20 mg Loading Dose PCI n=21 Participants Vorapaxar 20 mg as a loading dose is administered as the initial dose. From Day 2, 1mg or 2.5 mg once daily is administered as the maintenance dose for 59 days (total duration of 60 days).	Vorapaxar 40 mg Loading Dose PCI n=19 Participants Vorapaxar 40 mg as a loading dose is administered as the initial dose. From Day 2, 1 mg or 2.5 mg once daily is administered as the maintenance dose for 59 days (total duration of 60 days).	Placebo/Placebo PCI n=16 Participants Placebo as loading dose is administered as the initial dose. From Day 2, placebo once daily is administered as the maintenance dose for 59 days (total duration of 60 days).	Vorapaxar 40 mg/2.5 mg PCI n=15 Participants Vorapaxar 40 mg as loading dose is administered as the initial dose. From Day 2, 2.5 mg once daily is administered as the maintenance dose for 59 days (total duration of 60 days).	Placebo/Placebo PCI n=21 Participants Placebo as loading dose is administered as the initial dose. From Day 2, placebo once daily is administered as the maintenance dose for 59 days (total duration of 60 days).
Number of Participants Experiencing Non-Major Adverse Cardiac Events (MACE) Who Underwent PCI	21 Participants	19 Participants	16 Participants	14 Participants	21 Participants

SECONDARY outcome

Timeframe: Up to Day 60

Population: The population included all enrolled participants who received at least 1 dose of study drug and underwent PCI with TIMI bleeding data available.

Major TIMI bleeding was defined as any intracranial bleeding (excluding microhemorrhages \<10 mm evident only on gradient-echo magnetic resonance imaging \[MRI\]), clinically overt signs of hemorrhage associated with a drop in hemoglobin of ≥5 g/dL, or fatal bleeding (bleeding that directly results in death within 7 days). Minor TIMI bleeding was defined as any clinically overt bleeding resulting in hemoglobin drop of 3 to \<5 g/dL. Non-TIMI bleeding included all bleeding events not covered under Major TIMI bleeding or Minor TIMI bleeding. Analysis of data was by maintenance dose group.

Outcome measures

Outcome measures
Measure	Vorapaxar 20 mg Loading Dose PCI n=37 Participants Vorapaxar 20 mg as a loading dose is administered as the initial dose. From Day 2, 1mg or 2.5 mg once daily is administered as the maintenance dose for 59 days (total duration of 60 days).	Vorapaxar 40 mg Loading Dose PCI n=33 Participants Vorapaxar 40 mg as a loading dose is administered as the initial dose. From Day 2, 1 mg or 2.5 mg once daily is administered as the maintenance dose for 59 days (total duration of 60 days).	Placebo/Placebo PCI n=21 Participants Placebo as loading dose is administered as the initial dose. From Day 2, placebo once daily is administered as the maintenance dose for 59 days (total duration of 60 days).	Vorapaxar 40 mg/2.5 mg PCI Vorapaxar 40 mg as loading dose is administered as the initial dose. From Day 2, 2.5 mg once daily is administered as the maintenance dose for 59 days (total duration of 60 days).	Placebo/Placebo PCI Placebo as loading dose is administered as the initial dose. From Day 2, placebo once daily is administered as the maintenance dose for 59 days (total duration of 60 days).
Number of Participants With Major, Minor, and Non-Thrombolysis in Myocardial Infarction Cooperative Group (TIMI) Bleeding Events Among Participants Who Underwent PCI Major TIMI Bleeding Events	2 Participants	0 Participants	0 Participants	—	—
Number of Participants With Major, Minor, and Non-Thrombolysis in Myocardial Infarction Cooperative Group (TIMI) Bleeding Events Among Participants Who Underwent PCI Minor TIMI Bleeding Events	5 Participants	3 Participants	2 Participants	—	—
Number of Participants With Major, Minor, and Non-Thrombolysis in Myocardial Infarction Cooperative Group (TIMI) Bleeding Events Among Participants Who Underwent PCI Non-TIMI Bleeding Events	22 Participants	17 Participants	11 Participants	—	—

SECONDARY outcome

Timeframe: Baseline, Day 30, Day 60, Day 74, Day 90, Day 121

Population: The population consisted of all enrolled participants who received at least 1 dose of study drug and underwent PCI with inhibition of platelet aggregation data available.

Blood samples were collected from participants at Baseline and Days 30, 60, 74, 90, and 121 to determine the extent of inhibition of platelet aggregation induced by thrombin-receptor agonist peptide (TRAP). Analysis of data was by maintenance dose group.

Outcome measures

Outcome measures
Measure	Vorapaxar 20 mg Loading Dose PCI n=5 Participants Vorapaxar 20 mg as a loading dose is administered as the initial dose. From Day 2, 1mg or 2.5 mg once daily is administered as the maintenance dose for 59 days (total duration of 60 days).	Vorapaxar 40 mg Loading Dose PCI n=4 Participants Vorapaxar 40 mg as a loading dose is administered as the initial dose. From Day 2, 1 mg or 2.5 mg once daily is administered as the maintenance dose for 59 days (total duration of 60 days).	Placebo/Placebo PCI n=3 Participants Placebo as loading dose is administered as the initial dose. From Day 2, placebo once daily is administered as the maintenance dose for 59 days (total duration of 60 days).	Vorapaxar 40 mg/2.5 mg PCI Vorapaxar 40 mg as loading dose is administered as the initial dose. From Day 2, 2.5 mg once daily is administered as the maintenance dose for 59 days (total duration of 60 days).	Placebo/Placebo PCI Placebo as loading dose is administered as the initial dose. From Day 2, placebo once daily is administered as the maintenance dose for 59 days (total duration of 60 days).
Number of Participants Who Underwent PCI With Inhibition of Platelet Aggregation By Study Visit Baseline	5 Participants	4 Participants	3 Participants	—	—
Number of Participants Who Underwent PCI With Inhibition of Platelet Aggregation By Study Visit Day 30	5 Participants	4 Participants	3 Participants	—	—
Number of Participants Who Underwent PCI With Inhibition of Platelet Aggregation By Study Visit Day 60	3 Participants	3 Participants	1 Participants	—	—
Number of Participants Who Underwent PCI With Inhibition of Platelet Aggregation By Study Visit Day 74 (follow-up period)	5 Participants	4 Participants	3 Participants	—	—
Number of Participants Who Underwent PCI With Inhibition of Platelet Aggregation By Study Visit Day 90 (follow-up period)	5 Participants	4 Participants	3 Participants	—	—
Number of Participants Who Underwent PCI With Inhibition of Platelet Aggregation By Study Visit Day 121 (follow-up period)	5 Participants	4 Participants	3 Participants	—	—

SECONDARY outcome

Timeframe: Baseline, Day 30, Day 60

Population: The population included all enrolled participants who received at least 1 dose of study drug and underwent PCI with hs-CRP data available.

Participant blood samples were collected at Baseline and on Days 30 and 60 to evaluate the median level of hs-CRP. hs-CRP is a protein marker in the blood associated with inflammation with higher values indicating a greater degree of inflammation. Analysis of data was by maintenance dose group.

Outcome measures

Outcome measures
Measure	Vorapaxar 20 mg Loading Dose PCI n=37 Participants Vorapaxar 20 mg as a loading dose is administered as the initial dose. From Day 2, 1mg or 2.5 mg once daily is administered as the maintenance dose for 59 days (total duration of 60 days).	Vorapaxar 40 mg Loading Dose PCI n=34 Participants Vorapaxar 40 mg as a loading dose is administered as the initial dose. From Day 2, 1 mg or 2.5 mg once daily is administered as the maintenance dose for 59 days (total duration of 60 days).	Placebo/Placebo PCI n=21 Participants Placebo as loading dose is administered as the initial dose. From Day 2, placebo once daily is administered as the maintenance dose for 59 days (total duration of 60 days).	Vorapaxar 40 mg/2.5 mg PCI Vorapaxar 40 mg as loading dose is administered as the initial dose. From Day 2, 2.5 mg once daily is administered as the maintenance dose for 59 days (total duration of 60 days).	Placebo/Placebo PCI Placebo as loading dose is administered as the initial dose. From Day 2, placebo once daily is administered as the maintenance dose for 59 days (total duration of 60 days).
Median High-Sensitivity C-Reactive Protein (Hs-CRP) Levels Among Participants Who Underwent PCI By Study Visit Baseline (n=37, 34, 21)	1.30 mg/L Interval 0.54 to 4.5	2.00 mg/L Interval 0.61 to 8.36	1.78 mg/L Interval 0.66 to 4.5	—	—
Median High-Sensitivity C-Reactive Protein (Hs-CRP) Levels Among Participants Who Underwent PCI By Study Visit Day 30 (n=35, 34, 21)	1.28 mg/L Interval 0.43 to 7.9	1.01 mg/L Interval 0.7 to 5.62	2.99 mg/L Interval 1.14 to 9.4	—	—
Median High-Sensitivity C-Reactive Protein (Hs-CRP) Levels Among Participants Who Underwent PCI By Study Visit Day 60 (n=30, 25, 13)	1.20 mg/L Interval 0.39 to 3.0	0.79 mg/L Interval 0.44 to 2.02	1.27 mg/L Interval 0.61 to 4.88	—	—

SECONDARY outcome

Timeframe: Baseline, Day 30, Day 60

Population: The population included all enrolled participants who received at least 1 dose of study drug and underwent PCI with CD40 ligand data available.

Participant blood samples were collected at Baseline and Days 30 and 60 to evaluate the mean level of CD40 ligand present. CD40 ligand is a protein primarily found on activated T-cells, with higher levels indicating better immunological health. Analysis of data was by maintenance dose group.

Outcome measures

Outcome measures
Measure	Vorapaxar 20 mg Loading Dose PCI n=37 Participants Vorapaxar 20 mg as a loading dose is administered as the initial dose. From Day 2, 1mg or 2.5 mg once daily is administered as the maintenance dose for 59 days (total duration of 60 days).	Vorapaxar 40 mg Loading Dose PCI n=34 Participants Vorapaxar 40 mg as a loading dose is administered as the initial dose. From Day 2, 1 mg or 2.5 mg once daily is administered as the maintenance dose for 59 days (total duration of 60 days).	Placebo/Placebo PCI n=21 Participants Placebo as loading dose is administered as the initial dose. From Day 2, placebo once daily is administered as the maintenance dose for 59 days (total duration of 60 days).	Vorapaxar 40 mg/2.5 mg PCI Vorapaxar 40 mg as loading dose is administered as the initial dose. From Day 2, 2.5 mg once daily is administered as the maintenance dose for 59 days (total duration of 60 days).	Placebo/Placebo PCI Placebo as loading dose is administered as the initial dose. From Day 2, placebo once daily is administered as the maintenance dose for 59 days (total duration of 60 days).
Mean CD40 Ligand Levels Among Participants Who Underwent PCI Baseline (n=37, 34, 21)	5.6 ng/mL Standard Error 0.56 • Interval 0.54 to 4.5	6.9 ng/mL Standard Error 0.60 • Interval 0.61 to 8.36	4.8 ng/mL Standard Error 0.79 • Interval 0.66 to 4.5	—	—
Mean CD40 Ligand Levels Among Participants Who Underwent PCI Day 30 (n=35, 34, 31)	5.9 ng/mL Standard Error 0.52 • Interval 0.43 to 7.9	5.9 ng/mL Standard Error 0.63 • Interval 0.7 to 5.62	6.2 ng/mL Standard Error 0.73 • Interval 1.14 to 9.4	—	—
Mean CD40 Ligand Levels Among Participants Who Underwent PCI Day 60 (n=30, 25, 13)	5.6 ng/mL Standard Error 0.55 • Interval 0.39 to 3.0	5.4 ng/mL Standard Error 0.58 • Interval 0.44 to 2.02	5.7 ng/mL Standard Error 1.21 • Interval 0.61 to 4.88	—	—

SECONDARY outcome

Timeframe: Baseline, Day 30, Day 60

Population: The population included all enrolled participants that received at least 1 dose of study drug and underwent PCI with membrane-bound P-selectin data available.

Participant blood samples were collected at Baseline and Days 30 and 60 to evaluate the mean level of membrane-bound P-selectin. Membrane-bound P-selectin was measured using flow cytometry and a monoclonal antibody to P-selectin. Intensity levels are reported in arbitrary units 0 (dark) to 1023 (bright). Higher values correspond to greater membrane-bound P-Selectin levels. Analysis of data was by maintenance dose group.

Outcome measures

Outcome measures
Measure	Vorapaxar 20 mg Loading Dose PCI n=4 Participants Vorapaxar 20 mg as a loading dose is administered as the initial dose. From Day 2, 1mg or 2.5 mg once daily is administered as the maintenance dose for 59 days (total duration of 60 days).	Vorapaxar 40 mg Loading Dose PCI n=4 Participants Vorapaxar 40 mg as a loading dose is administered as the initial dose. From Day 2, 1 mg or 2.5 mg once daily is administered as the maintenance dose for 59 days (total duration of 60 days).	Placebo/Placebo PCI n=3 Participants Placebo as loading dose is administered as the initial dose. From Day 2, placebo once daily is administered as the maintenance dose for 59 days (total duration of 60 days).	Vorapaxar 40 mg/2.5 mg PCI Vorapaxar 40 mg as loading dose is administered as the initial dose. From Day 2, 2.5 mg once daily is administered as the maintenance dose for 59 days (total duration of 60 days).	Placebo/Placebo PCI Placebo as loading dose is administered as the initial dose. From Day 2, placebo once daily is administered as the maintenance dose for 59 days (total duration of 60 days).
Mean Membrane-Bound P-Selectin Levels Among Participants Who Underwent PCI Baseline (n=4, 4, 3)	24.8 Arbitrary Units Standard Error 2.86 • Interval 0.54 to 4.5	16.5 Arbitrary Units Standard Error 0.83 • Interval 0.61 to 8.36	15.9 Arbitrary Units Standard Error 1.25 • Interval 0.66 to 4.5	—	—
Mean Membrane-Bound P-Selectin Levels Among Participants Who Underwent PCI Day 30 (n=3, 4, 3)	20.6 Arbitrary Units Standard Error 1.76 • Interval 0.43 to 7.9	16.4 Arbitrary Units Standard Error 0.85 • Interval 0.7 to 5.62	18.8 Arbitrary Units Standard Error 0.91 • Interval 1.14 to 9.4	—	—
Mean Membrane-Bound P-Selectin Levels Among Participants Who Underwent PCI Day 60 (n=2, 3, 1)	25.0 Arbitrary Units Standard Error 2.80 • Interval 0.39 to 3.0	14.9 Arbitrary Units Standard Error 0.62 • Interval 0.44 to 2.02	19.4 Arbitrary Units Standard Error NA • Interval 0.61 to 4.88 SE not calculable since n=1.	—	—

SECONDARY outcome

Timeframe: Up to Day 121

Population: The population included all participants who received at least 1 dose of study drug, underwent PCI, and had bleeding event data.

Clinically important bleeding events were defined as intracranial hemorrhage, bleeding requiring hospitalization, or TIMI major bleeding. Analysis of data was by loading/maintenance dose group.

Outcome measures

Outcome measures
Measure	Vorapaxar 20 mg Loading Dose PCI n=21 Participants Vorapaxar 20 mg as a loading dose is administered as the initial dose. From Day 2, 1mg or 2.5 mg once daily is administered as the maintenance dose for 59 days (total duration of 60 days).	Vorapaxar 40 mg Loading Dose PCI n=19 Participants Vorapaxar 40 mg as a loading dose is administered as the initial dose. From Day 2, 1 mg or 2.5 mg once daily is administered as the maintenance dose for 59 days (total duration of 60 days).	Placebo/Placebo PCI n=16 Participants Placebo as loading dose is administered as the initial dose. From Day 2, placebo once daily is administered as the maintenance dose for 59 days (total duration of 60 days).	Vorapaxar 40 mg/2.5 mg PCI n=15 Participants Vorapaxar 40 mg as loading dose is administered as the initial dose. From Day 2, 2.5 mg once daily is administered as the maintenance dose for 59 days (total duration of 60 days).	Placebo/Placebo PCI n=21 Participants Placebo as loading dose is administered as the initial dose. From Day 2, placebo once daily is administered as the maintenance dose for 59 days (total duration of 60 days).
Number of Participants Who Underwent PCI With Clinically Important Bleeding Events During Treatment and After Hospital Discharge Treatment Phase	3 Participants	0 Participants	2 Participants	0 Participants	0 Participants
Number of Participants Who Underwent PCI With Clinically Important Bleeding Events During Treatment and After Hospital Discharge Post-Hospital Discharge	1 Participants	0 Participants	2 Participants	0 Participants	0 Participants

SECONDARY outcome

Timeframe: Up to Day 60

Population: The population consisted of all enrolled participants who received at least 1 dose of study drug, did not undergo PCI, and had TIMI bleeding data available.

Major TIMI bleeding was defined as any intracranial bleeding (excluding microhemorrhages \<10 mm evident only on gradient-echo MRI), clinically overt signs of hemorrhage associated with a drop in hemoglobin of ≥5 g/dL, or fatal bleeding (bleeding that directly results in death within 7 days). Minor TIMI bleeding was defined as any clinically overt bleeding resulting in hemoglobin drop of 3 to \<5 g/dL. Non-TIMI bleeding included all bleeding events not covered under Major TIMI bleeding or Minor TIMI bleeding. Analysis of data was by loading dose group.

Outcome measures

Outcome measures
Measure	Vorapaxar 20 mg Loading Dose PCI n=6 Participants Vorapaxar 20 mg as a loading dose is administered as the initial dose. From Day 2, 1mg or 2.5 mg once daily is administered as the maintenance dose for 59 days (total duration of 60 days).	Vorapaxar 40 mg Loading Dose PCI n=17 Participants Vorapaxar 40 mg as a loading dose is administered as the initial dose. From Day 2, 1 mg or 2.5 mg once daily is administered as the maintenance dose for 59 days (total duration of 60 days).	Placebo/Placebo PCI n=2 Participants Placebo as loading dose is administered as the initial dose. From Day 2, placebo once daily is administered as the maintenance dose for 59 days (total duration of 60 days).	Vorapaxar 40 mg/2.5 mg PCI Vorapaxar 40 mg as loading dose is administered as the initial dose. From Day 2, 2.5 mg once daily is administered as the maintenance dose for 59 days (total duration of 60 days).	Placebo/Placebo PCI Placebo as loading dose is administered as the initial dose. From Day 2, placebo once daily is administered as the maintenance dose for 59 days (total duration of 60 days).
Number of Participants With Major, Minor, and Non-TIMI Bleeding Events Among Participants Who Did Not Undergo PCI Major TIMI Events	1 Participants	2 Participants	0 Participants	—	—
Number of Participants With Major, Minor, and Non-TIMI Bleeding Events Among Participants Who Did Not Undergo PCI Minor TIMI Events	0 Participants	0 Participants	0 Participants	—	—
Number of Participants With Major, Minor, and Non-TIMI Bleeding Events Among Participants Who Did Not Undergo PCI Non-TIMI Bleeding Events	1 Participants	8 Participants	1 Participants	—	—

SECONDARY outcome

Timeframe: Up to Day 121

Population: The population consisted of all enrolled participants who received at least 1 dose of study drug, did not undergo PCI, and had non-MACE AE data available.

An AE is any unfavorable and unintended change in the structure, function or chemistry of the body temporally associated with study drug administration, whether or not considered related to the study drug. MACE events were defined as nonfatal MI, nonfatal stroke, hospitalization due to recurrent ischemia, or urgent coronary revascularization performed ≥ 30 days after administration of the loading dose (Day 1). All MACE events were excluded from this analysis. Analysis of data was by loading dose group.

Outcome measures

Outcome measures
Measure	Vorapaxar 20 mg Loading Dose PCI n=6 Participants Vorapaxar 20 mg as a loading dose is administered as the initial dose. From Day 2, 1mg or 2.5 mg once daily is administered as the maintenance dose for 59 days (total duration of 60 days).	Vorapaxar 40 mg Loading Dose PCI n=17 Participants Vorapaxar 40 mg as a loading dose is administered as the initial dose. From Day 2, 1 mg or 2.5 mg once daily is administered as the maintenance dose for 59 days (total duration of 60 days).	Placebo/Placebo PCI n=2 Participants Placebo as loading dose is administered as the initial dose. From Day 2, placebo once daily is administered as the maintenance dose for 59 days (total duration of 60 days).	Vorapaxar 40 mg/2.5 mg PCI Vorapaxar 40 mg as loading dose is administered as the initial dose. From Day 2, 2.5 mg once daily is administered as the maintenance dose for 59 days (total duration of 60 days).	Placebo/Placebo PCI Placebo as loading dose is administered as the initial dose. From Day 2, placebo once daily is administered as the maintenance dose for 59 days (total duration of 60 days).
Number of Participants Experiencing Non-MACE AEs Among Participants Who Did Not Undergo PCI	6 Participants	15 Participants	1 Participants	—	—

SECONDARY outcome

Timeframe: Up to 10 Hours Post-CABG

Population: Evaluation of the bleeding events associated with CABG occurring after Vorapaxar treatment was not analyzed since only three participants in the non-PCI cohort underwent CABG in this study.

Bleeding events were evaluated up to 10 hours post-CABG among participants who did not undergo PCI.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Up to Day 60

Population: The population consisted of all enrolled participants who received at least 1 dose of study drug, did not undergo PCI, and had transfusion data available.

Bleeding events were evaluated among participants that did not undergo PCI to determine the number of participants that required blood transfusion. Analysis of data was by loading dose group.

Outcome measures

Outcome measures
Measure	Vorapaxar 20 mg Loading Dose PCI n=6 Participants Vorapaxar 20 mg as a loading dose is administered as the initial dose. From Day 2, 1mg or 2.5 mg once daily is administered as the maintenance dose for 59 days (total duration of 60 days).	Vorapaxar 40 mg Loading Dose PCI n=17 Participants Vorapaxar 40 mg as a loading dose is administered as the initial dose. From Day 2, 1 mg or 2.5 mg once daily is administered as the maintenance dose for 59 days (total duration of 60 days).	Placebo/Placebo PCI n=2 Participants Placebo as loading dose is administered as the initial dose. From Day 2, placebo once daily is administered as the maintenance dose for 59 days (total duration of 60 days).	Vorapaxar 40 mg/2.5 mg PCI Vorapaxar 40 mg as loading dose is administered as the initial dose. From Day 2, 2.5 mg once daily is administered as the maintenance dose for 59 days (total duration of 60 days).	Placebo/Placebo PCI Placebo as loading dose is administered as the initial dose. From Day 2, placebo once daily is administered as the maintenance dose for 59 days (total duration of 60 days).
Number of Participants Who Did Not Undergo PCI But Had Bleeding Events That Required Transfusion	1 Participants	2 Participants	0 Participants	—	—

SECONDARY outcome

Timeframe: Up to Day 30

Population: The population consisted of all enrolled participants who received at least 1 dose of study drug, did not undergo PCI, and had hospitalization data available.

Bleeding events were evaluated among participants that did not undergo PCI to determine the number of participants who required a subsequent hospitalization. Analysis of data was by loading dose group.

Outcome measures

Outcome measures
Measure	Vorapaxar 20 mg Loading Dose PCI n=6 Participants Vorapaxar 20 mg as a loading dose is administered as the initial dose. From Day 2, 1mg or 2.5 mg once daily is administered as the maintenance dose for 59 days (total duration of 60 days).	Vorapaxar 40 mg Loading Dose PCI n=17 Participants Vorapaxar 40 mg as a loading dose is administered as the initial dose. From Day 2, 1 mg or 2.5 mg once daily is administered as the maintenance dose for 59 days (total duration of 60 days).	Placebo/Placebo PCI n=2 Participants Placebo as loading dose is administered as the initial dose. From Day 2, placebo once daily is administered as the maintenance dose for 59 days (total duration of 60 days).	Vorapaxar 40 mg/2.5 mg PCI Vorapaxar 40 mg as loading dose is administered as the initial dose. From Day 2, 2.5 mg once daily is administered as the maintenance dose for 59 days (total duration of 60 days).	Placebo/Placebo PCI Placebo as loading dose is administered as the initial dose. From Day 2, placebo once daily is administered as the maintenance dose for 59 days (total duration of 60 days).
Number of Participants Who Did Not Undergo PCI But Had Bleeding Events That Required Subsequent Hospitalization	0 Participants	1 Participants	0 Participants	—	—

SECONDARY outcome

Timeframe: Baseline Up To Day 60

Population: The population consisted of all enrolled participants who received at least 1 dose of study drug, did not undergo PCI, and had hs-CRP data available.

Participant blood samples were collected at baseline and at the time of hospital discharge to determine the median serum level of hs-CRP. Analysis of data was by loading dose group.

Outcome measures

Outcome measures
Measure	Vorapaxar 20 mg Loading Dose PCI n=6 Participants Vorapaxar 20 mg as a loading dose is administered as the initial dose. From Day 2, 1mg or 2.5 mg once daily is administered as the maintenance dose for 59 days (total duration of 60 days).	Vorapaxar 40 mg Loading Dose PCI n=17 Participants Vorapaxar 40 mg as a loading dose is administered as the initial dose. From Day 2, 1 mg or 2.5 mg once daily is administered as the maintenance dose for 59 days (total duration of 60 days).	Placebo/Placebo PCI n=2 Participants Placebo as loading dose is administered as the initial dose. From Day 2, placebo once daily is administered as the maintenance dose for 59 days (total duration of 60 days).	Vorapaxar 40 mg/2.5 mg PCI Vorapaxar 40 mg as loading dose is administered as the initial dose. From Day 2, 2.5 mg once daily is administered as the maintenance dose for 59 days (total duration of 60 days).	Placebo/Placebo PCI Placebo as loading dose is administered as the initial dose. From Day 2, placebo once daily is administered as the maintenance dose for 59 days (total duration of 60 days).
Median Hs-CRP Levels Among Participants Who Did Not Undergo PCI Baseline	2.57 mg/L Standard Deviation 5.70	1.05 mg/L Standard Deviation 2.23	6.94 mg/L Standard Deviation 12.01	—	—
Median Hs-CRP Levels Among Participants Who Did Not Undergo PCI Time of Hospital Discharge	3.56 mg/L Standard Deviation 10.12	2.65 mg/L Standard Deviation 5.00	3.96 mg/L Standard Deviation 0.91	—	—

SECONDARY outcome

Timeframe: Baseline Up To Day 60

Population: The population consisted of all enrolled participants who received at least 1 dose of study drug, did not undergo PCI, and had CD40 ligand data available.

Participant blood samples were collected at baseline and at the time of hospital discharge to determine the mean serum level of CD40 ligand. Analysis of data was by loading dose group.

Outcome measures

Outcome measures
Measure	Vorapaxar 20 mg Loading Dose PCI n=6 Participants Vorapaxar 20 mg as a loading dose is administered as the initial dose. From Day 2, 1mg or 2.5 mg once daily is administered as the maintenance dose for 59 days (total duration of 60 days).	Vorapaxar 40 mg Loading Dose PCI n=17 Participants Vorapaxar 40 mg as a loading dose is administered as the initial dose. From Day 2, 1 mg or 2.5 mg once daily is administered as the maintenance dose for 59 days (total duration of 60 days).	Placebo/Placebo PCI n=2 Participants Placebo as loading dose is administered as the initial dose. From Day 2, placebo once daily is administered as the maintenance dose for 59 days (total duration of 60 days).	Vorapaxar 40 mg/2.5 mg PCI Vorapaxar 40 mg as loading dose is administered as the initial dose. From Day 2, 2.5 mg once daily is administered as the maintenance dose for 59 days (total duration of 60 days).	Placebo/Placebo PCI Placebo as loading dose is administered as the initial dose. From Day 2, placebo once daily is administered as the maintenance dose for 59 days (total duration of 60 days).
Mean CD40 Ligand Levels Among Participants Who Did Not Undergo PCI Time of Hospital Discharge	10.1 ng/mL Standard Error 2.86	7.1 ng/mL Standard Error 0.83	12.9 ng/mL Standard Error 4.64	—	—
Mean CD40 Ligand Levels Among Participants Who Did Not Undergo PCI Baseline	8.4 ng/mL Standard Error 1.10	4.6 ng/mL Standard Error 0.79	11.1 ng/mL Standard Error 4.06	—	—

SECONDARY outcome

Timeframe: Baseline Up To Day 60

Population: The population consisted of all enrolled participants who received at least 1 dose of study drug, did not undergo PCI, and had bleeding event data available.

Clinically important bleeding events were defined as intracranial hemorrhage, bleeding requiring blood transfusion, bleeding requiring hospitalization, and TIMI major bleeding. Analysis of data was by loading dose group.

Outcome measures

Outcome measures
Measure	Vorapaxar 20 mg Loading Dose PCI n=6 Participants Vorapaxar 20 mg as a loading dose is administered as the initial dose. From Day 2, 1mg or 2.5 mg once daily is administered as the maintenance dose for 59 days (total duration of 60 days).	Vorapaxar 40 mg Loading Dose PCI n=17 Participants Vorapaxar 40 mg as a loading dose is administered as the initial dose. From Day 2, 1 mg or 2.5 mg once daily is administered as the maintenance dose for 59 days (total duration of 60 days).	Placebo/Placebo PCI n=2 Participants Placebo as loading dose is administered as the initial dose. From Day 2, placebo once daily is administered as the maintenance dose for 59 days (total duration of 60 days).	Vorapaxar 40 mg/2.5 mg PCI Vorapaxar 40 mg as loading dose is administered as the initial dose. From Day 2, 2.5 mg once daily is administered as the maintenance dose for 59 days (total duration of 60 days).	Placebo/Placebo PCI Placebo as loading dose is administered as the initial dose. From Day 2, placebo once daily is administered as the maintenance dose for 59 days (total duration of 60 days).
Number of Participants Who Did Not Undergo PCI That Had Clinically Important Bleeding Events Intracranial hemorrhage	0 Participants 1.10	1 Participants 0.79	0 Participants 4.06	—	—
Number of Participants Who Did Not Undergo PCI That Had Clinically Important Bleeding Events Bleeding requiring transfusion	1 Participants 2.86	2 Participants 0.83	0 Participants 4.64	—	—
Number of Participants Who Did Not Undergo PCI That Had Clinically Important Bleeding Events Bleeding requiring hospitalization	0 Participants	1 Participants	0 Participants	—	—
Number of Participants Who Did Not Undergo PCI That Had Clinically Important Bleeding Events Major TIMI bleeding	1 Participants	2 Participants	0 Participants	—	—

Adverse Events

Vorapaxar 20 mg/1 mg

Serious events: 5 serious events

Other events: 25 other events

Deaths: 0 deaths

Vorapaxar 20 mg/2.5 mg

Serious events: 4 serious events

Other events: 23 other events

Deaths: 0 deaths

Vorapaxar 40 mg/1 mg

Serious events: 2 serious events

Other events: 22 other events

Deaths: 0 deaths

Vorapaxar 40 mg/2.5 mg

Serious events: 2 serious events

Other events: 23 other events

Deaths: 0 deaths

Placebo/Placebo

Serious events: 5 serious events

Other events: 22 other events

Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure	Vorapaxar 20 mg/1 mg n=25 participants at risk Vorapaxar 20 mg as loading dose is administered as the initial dose. From Day 2, 1 mg once daily is administered as the maintenance dose for 59 days (total duration of 60 days).	Vorapaxar 20 mg/2.5 mg n=24 participants at risk Vorapaxar 20 mg as loading dose is administered as the initial dose. From Day 2, 2.5 mg once daily is administered as the maintenance dose for 59 days (total duration of 60 days).	Vorapaxar 40 mg/1 mg n=22 participants at risk Vorapaxar 40 mg as loading dose is administered as the initial dose. From Day 2, 1 mg once daily is administered as the maintenance dose for 59 days (total duration of 60 days).	Vorapaxar 40 mg/2.5 mg n=26 participants at risk Vorapaxar 40 mg as loading dose is administered as the initial dose. From Day 2, 2.5 mg once daily is administered as the maintenance dose for 59 days (total duration of 60 days).	Placebo/Placebo n=23 participants at risk Placebo as loading dose is administered as the initial dose. From Day 2, placebo once daily is administered as the maintenance dose for 59 days (total duration of 60 days).
Cardiac disorders Acute Myocardial Infarction	4.0% 1/25 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/24 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/22 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/26 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/23 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
Cardiac disorders Cardiac Tamponade	4.0% 1/25 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/24 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/22 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/26 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/23 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
Cardiac disorders Supraventricular Extrasystoles	0.00% 0/25 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/24 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/22 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	3.8% 1/26 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/23 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
Cardiac disorders Ventricle Rupture	4.0% 1/25 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/24 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/22 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/26 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/23 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
Cardiac disorders Ventricular Extrasystoles	0.00% 0/25 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/24 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/22 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	3.8% 1/26 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/23 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
Ear and labyrinth disorders Sudden Hearing Loss	4.0% 1/25 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/24 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/22 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/26 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/23 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
Gastrointestinal disorders Inguinal Hernia	0.00% 0/25 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/24 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/22 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/26 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	4.3% 1/23 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
Gastrointestinal disorders Malaena	4.0% 1/25 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/24 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/22 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/26 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/23 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
General disorders Chest Discomfort	0.00% 0/25 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	4.2% 1/24 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/22 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/26 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/23 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
Infections and infestations Bronchitis	4.0% 1/25 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/24 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/22 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/26 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/23 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
Infections and infestations Cellulitis	0.00% 0/25 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/24 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	4.5% 1/22 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/26 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/23 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
Infections and infestations Pyelonephritis	0.00% 0/25 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/24 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/22 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/26 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	4.3% 1/23 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
Infections and infestations Sepsis	0.00% 0/25 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/24 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/22 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/26 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	4.3% 1/23 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
Injury, poisoning and procedural complications Post Procedural Haematoma	0.00% 0/25 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/24 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	4.5% 1/22 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/26 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/23 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
Injury, poisoning and procedural complications Post Procedural Haemorrhage	4.0% 1/25 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/24 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/22 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/26 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/23 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
Injury, poisoning and procedural complications Rib Fracture	0.00% 0/25 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/24 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/22 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	3.8% 1/26 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/23 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
Investigations Alanine Aminotransferase Increased	0.00% 0/25 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/24 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/22 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/26 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	4.3% 1/23 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
Investigations Blood Glucose Increased	4.0% 1/25 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/24 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/22 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/26 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/23 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
Musculoskeletal and connective tissue disorders Rheumatoid Arthritis	0.00% 0/25 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	4.2% 1/24 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/22 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/26 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/23 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Colon Adenoma	0.00% 0/25 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	4.2% 1/24 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/22 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/26 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/23 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Colon Cancer	0.00% 0/25 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	4.2% 1/24 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/22 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/26 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/23 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
Nervous system disorders Loss of Consciousness	0.00% 0/25 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/24 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/22 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	3.8% 1/26 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/23 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
Nervous system disorders Subarachnoid Haemorrhage	0.00% 0/25 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/24 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/22 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	3.8% 1/26 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/23 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
Renal and urinary disorders Renal Failure Acute	0.00% 0/25 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/24 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/22 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/26 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	4.3% 1/23 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
Skin and subcutaneous tissue disorders Rash	0.00% 0/25 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/24 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/22 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/26 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	4.3% 1/23 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
Vascular disorders Arteriosclerosis Obliterans	0.00% 0/25 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/24 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/22 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/26 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	4.3% 1/23 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.

Other adverse events

Other adverse events
Measure	Vorapaxar 20 mg/1 mg n=25 participants at risk Vorapaxar 20 mg as loading dose is administered as the initial dose. From Day 2, 1 mg once daily is administered as the maintenance dose for 59 days (total duration of 60 days).	Vorapaxar 20 mg/2.5 mg n=24 participants at risk Vorapaxar 20 mg as loading dose is administered as the initial dose. From Day 2, 2.5 mg once daily is administered as the maintenance dose for 59 days (total duration of 60 days).	Vorapaxar 40 mg/1 mg n=22 participants at risk Vorapaxar 40 mg as loading dose is administered as the initial dose. From Day 2, 1 mg once daily is administered as the maintenance dose for 59 days (total duration of 60 days).	Vorapaxar 40 mg/2.5 mg n=26 participants at risk Vorapaxar 40 mg as loading dose is administered as the initial dose. From Day 2, 2.5 mg once daily is administered as the maintenance dose for 59 days (total duration of 60 days).	Placebo/Placebo n=23 participants at risk Placebo as loading dose is administered as the initial dose. From Day 2, placebo once daily is administered as the maintenance dose for 59 days (total duration of 60 days).
Blood and lymphatic system disorders Anaemia	8.0% 2/25 • Number of events 2 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/24 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/22 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/26 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/23 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
Cardiac disorders Arrhythmia	0.00% 0/25 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	4.2% 1/24 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/22 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	7.7% 2/26 • Number of events 2 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/23 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
Cardiac disorders Atrial Fibrillation	0.00% 0/25 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/24 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	4.5% 1/22 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	7.7% 2/26 • Number of events 2 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/23 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
Cardiac disorders Bradycardia	0.00% 0/25 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	12.5% 3/24 • Number of events 3 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/22 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	3.8% 1/26 • Number of events 2 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	4.3% 1/23 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
Cardiac disorders Myocardial Infarction	12.0% 3/25 • Number of events 3 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	12.5% 3/24 • Number of events 3 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	22.7% 5/22 • Number of events 5 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	7.7% 2/26 • Number of events 2 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	39.1% 9/23 • Number of events 10 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
Cardiac disorders Palpitations	0.00% 0/25 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/24 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	18.2% 4/22 • Number of events 4 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	3.8% 1/26 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/23 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
Cardiac disorders Ventricular Extrasystoles	0.00% 0/25 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/24 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/22 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	3.8% 1/26 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	8.7% 2/23 • Number of events 2 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
Gastrointestinal disorders Abdominal Distention	0.00% 0/25 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/24 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/22 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	7.7% 2/26 • Number of events 2 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/23 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
Gastrointestinal disorders Constipation	24.0% 6/25 • Number of events 7 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	29.2% 7/24 • Number of events 8 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	13.6% 3/22 • Number of events 3 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	15.4% 4/26 • Number of events 5 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	26.1% 6/23 • Number of events 7 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
Gastrointestinal disorders Diarrhoea	16.0% 4/25 • Number of events 5 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	8.3% 2/24 • Number of events 2 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/22 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	3.8% 1/26 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	8.7% 2/23 • Number of events 2 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
Gastrointestinal disorders Gingival Bleeding	0.00% 0/25 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/24 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	4.5% 1/22 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	7.7% 2/26 • Number of events 2 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/23 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
Gastrointestinal disorders Haemorrhoids	0.00% 0/25 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/24 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	9.1% 2/22 • Number of events 2 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	3.8% 1/26 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/23 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
Gastrointestinal disorders Nausea	4.0% 1/25 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	8.3% 2/24 • Number of events 2 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	4.5% 1/22 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	3.8% 1/26 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	8.7% 2/23 • Number of events 2 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
Gastrointestinal disorders Periodontitis	0.00% 0/25 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/24 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/22 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/26 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	8.7% 2/23 • Number of events 2 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
Gastrointestinal disorders Stomatitis	0.00% 0/25 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	8.3% 2/24 • Number of events 3 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	4.5% 1/22 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	3.8% 1/26 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	4.3% 1/23 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
General disorders Chest Discomfort	12.0% 3/25 • Number of events 3 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	12.5% 3/24 • Number of events 3 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	13.6% 3/22 • Number of events 4 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	15.4% 4/26 • Number of events 4 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	8.7% 2/23 • Number of events 2 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
General disorders Chest Pain	8.0% 2/25 • Number of events 2 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	12.5% 3/24 • Number of events 9 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	4.5% 1/22 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	7.7% 2/26 • Number of events 2 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	8.7% 2/23 • Number of events 2 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
General disorders Oedema Peripheral	8.0% 2/25 • Number of events 2 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/24 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	4.5% 1/22 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/26 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/23 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
General disorders Puncture Site Haemorrhage	8.0% 2/25 • Number of events 2 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/24 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	4.5% 1/22 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/26 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	8.7% 2/23 • Number of events 2 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
General disorders Puncture Site Pain	4.0% 1/25 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/24 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	18.2% 4/22 • Number of events 5 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/26 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	4.3% 1/23 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
General disorders Pyrexia	24.0% 6/25 • Number of events 7 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	12.5% 3/24 • Number of events 3 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	13.6% 3/22 • Number of events 3 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/26 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	13.0% 3/23 • Number of events 3 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
General disorders Venipuncture Site Swelling	8.0% 2/25 • Number of events 2 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/24 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/22 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/26 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/23 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
Hepatobiliary disorders Hepatic Function Abnormal	8.0% 2/25 • Number of events 2 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	4.2% 1/24 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	9.1% 2/22 • Number of events 2 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	19.2% 5/26 • Number of events 5 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	13.0% 3/23 • Number of events 3 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
Infections and infestations Gingival Abscess	0.00% 0/25 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/24 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/22 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/26 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	8.7% 2/23 • Number of events 2 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
Infections and infestations Nasopharyngitis	16.0% 4/25 • Number of events 5 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	16.7% 4/24 • Number of events 4 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	22.7% 5/22 • Number of events 5 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	7.7% 2/26 • Number of events 3 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	13.0% 3/23 • Number of events 3 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
Injury, poisoning and procedural complications Post Procedural Haematoma	12.0% 3/25 • Number of events 3 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	8.3% 2/24 • Number of events 2 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	9.1% 2/22 • Number of events 2 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	7.7% 2/26 • Number of events 3 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	17.4% 4/23 • Number of events 5 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
Injury, poisoning and procedural complications Post Procedural Haemorrhage	4.0% 1/25 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	12.5% 3/24 • Number of events 3 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	13.6% 3/22 • Number of events 3 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	11.5% 3/26 • Number of events 3 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	17.4% 4/23 • Number of events 4 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
Investigations Alanine Aminotransferase Increased	0.00% 0/25 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	8.3% 2/24 • Number of events 2 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/22 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/26 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	8.7% 2/23 • Number of events 2 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
Investigations Aspartate Aminotransferase Increased	0.00% 0/25 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/24 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/22 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/26 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	8.7% 2/23 • Number of events 2 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
Investigations Blood Alkaline Phosphatase Increased	4.0% 1/25 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/24 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/22 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	3.8% 1/26 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	8.7% 2/23 • Number of events 2 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
Investigations Blood Creatine Phosphokinase Increased	0.00% 0/25 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/24 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	13.6% 3/22 • Number of events 3 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	7.7% 2/26 • Number of events 2 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	4.3% 1/23 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
Investigations Blood Creatinine Increased	0.00% 0/25 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/24 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/22 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	7.7% 2/26 • Number of events 2 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/23 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
Investigations Blood Pressure Decreased	8.0% 2/25 • Number of events 5 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/24 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/22 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	3.8% 1/26 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/23 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
Investigations Blood Pressure Increased	0.00% 0/25 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	4.2% 1/24 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/22 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	7.7% 2/26 • Number of events 2 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	4.3% 1/23 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
Investigations Blood Triglycerides Increased	0.00% 0/25 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	12.5% 3/24 • Number of events 4 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/22 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	3.8% 1/26 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/23 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
Investigations Blood Urine Present	16.0% 4/25 • Number of events 5 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	4.2% 1/24 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	9.1% 2/22 • Number of events 3 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	11.5% 3/26 • Number of events 3 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	8.7% 2/23 • Number of events 3 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
Investigations Gamma-Glutamyltransferase Increased	0.00% 0/25 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	4.2% 1/24 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/22 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	7.7% 2/26 • Number of events 3 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	8.7% 2/23 • Number of events 2 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
Investigations Haemoglobin Decreased	4.0% 1/25 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	12.5% 3/24 • Number of events 3 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	9.1% 2/22 • Number of events 2 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	3.8% 1/26 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	8.7% 2/23 • Number of events 3 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
Investigations Occult Blood	16.0% 4/25 • Number of events 4 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	8.3% 2/24 • Number of events 2 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	4.5% 1/22 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/26 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/23 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
Investigations Occult Blood Positive	48.0% 12/25 • Number of events 13 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	33.3% 8/24 • Number of events 8 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	45.5% 10/22 • Number of events 10 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	26.9% 7/26 • Number of events 9 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	43.5% 10/23 • Number of events 10 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
Investigations Protein Urine Present	8.0% 2/25 • Number of events 2 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	4.2% 1/24 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	9.1% 2/22 • Number of events 2 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/26 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/23 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
Investigations White Blood Cell Count Decreased	0.00% 0/25 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	4.2% 1/24 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/22 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	7.7% 2/26 • Number of events 2 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	8.7% 2/23 • Number of events 2 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
Metabolism and nutrition disorders Hyperchlesterolaemia	4.0% 1/25 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/24 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/22 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/26 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	13.0% 3/23 • Number of events 3 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
Metabolism and nutrition disorders Hypoglycaemia	4.0% 1/25 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/24 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/22 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	7.7% 2/26 • Number of events 2 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	4.3% 1/23 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
Musculoskeletal and connective tissue disorders Back Pain	8.0% 2/25 • Number of events 2 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	4.2% 1/24 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	31.8% 7/22 • Number of events 8 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	11.5% 3/26 • Number of events 3 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	13.0% 3/23 • Number of events 4 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
Musculoskeletal and connective tissue disorders Myalgia	0.00% 0/25 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	4.2% 1/24 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	9.1% 2/22 • Number of events 2 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/26 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	4.3% 1/23 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
Musculoskeletal and connective tissue disorders Pain in Extremity	4.0% 1/25 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	12.5% 3/24 • Number of events 3 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	4.5% 1/22 • Number of events 3 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/26 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/23 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
Nervous system disorders Dizziness	8.0% 2/25 • Number of events 2 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/24 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	4.5% 1/22 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	3.8% 1/26 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	4.3% 1/23 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
Nervous system disorders Dizziness Postural	4.0% 1/25 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/24 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	4.5% 1/22 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/26 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	8.7% 2/23 • Number of events 2 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
Nervous system disorders Headache	12.0% 3/25 • Number of events 3 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	4.2% 1/24 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	22.7% 5/22 • Number of events 5 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	11.5% 3/26 • Number of events 3 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	21.7% 5/23 • Number of events 5 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
Nervous system disorders Hypoaesthesia	0.00% 0/25 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	4.2% 1/24 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	9.1% 2/22 • Number of events 2 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/26 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/23 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
Psychiatric disorders Insomnia	20.0% 5/25 • Number of events 5 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	12.5% 3/24 • Number of events 3 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	9.1% 2/22 • Number of events 2 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	26.9% 7/26 • Number of events 7 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	13.0% 3/23 • Number of events 3 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
Psychiatric disorders Restlessness	12.0% 3/25 • Number of events 3 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/24 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/22 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/26 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/23 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
Renal and urinary disorders Haematuria	8.0% 2/25 • Number of events 2 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	4.2% 1/24 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/22 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	3.8% 1/26 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	13.0% 3/23 • Number of events 3 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
Renal and urinary disorders Oliguria	0.00% 0/25 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	4.2% 1/24 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	4.5% 1/22 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/26 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	8.7% 2/23 • Number of events 2 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
Respiratory, thoracic and mediastinal disorders Cough	8.0% 2/25 • Number of events 2 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/24 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	4.5% 1/22 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	3.8% 1/26 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	4.3% 1/23 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
Respiratory, thoracic and mediastinal disorders Epistaxis	12.0% 3/25 • Number of events 4 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	16.7% 4/24 • Number of events 5 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/22 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	15.4% 4/26 • Number of events 4 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	8.7% 2/23 • Number of events 2 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
Respiratory, thoracic and mediastinal disorders Haemoptysis	8.0% 2/25 • Number of events 2 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/24 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/22 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/26 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	4.3% 1/23 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
Skin and subcutaneous tissue disorders Blister	0.00% 0/25 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/24 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	9.1% 2/22 • Number of events 2 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	3.8% 1/26 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	4.3% 1/23 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
Skin and subcutaneous tissue disorders Cold Sweat	0.00% 0/25 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	4.2% 1/24 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	9.1% 2/22 • Number of events 2 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/26 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/23 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
Skin and subcutaneous tissue disorders Drug Eruption	4.0% 1/25 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	8.3% 2/24 • Number of events 2 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/22 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	7.7% 2/26 • Number of events 2 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/23 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
Skin and subcutaneous tissue disorders Erythema	8.0% 2/25 • Number of events 2 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	4.2% 1/24 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/22 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	3.8% 1/26 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/23 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
Skin and subcutaneous tissue disorders Haemorrhage Subcutaneous	4.0% 1/25 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	8.3% 2/24 • Number of events 3 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	18.2% 4/22 • Number of events 4 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	7.7% 2/26 • Number of events 2 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/23 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
Skin and subcutaneous tissue disorders Pruritus	4.0% 1/25 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/24 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	9.1% 2/22 • Number of events 2 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/26 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	4.3% 1/23 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
Skin and subcutaneous tissue disorders Purpura	8.0% 2/25 • Number of events 2 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	8.3% 2/24 • Number of events 2 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	4.5% 1/22 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	7.7% 2/26 • Number of events 2 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/23 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
Skin and subcutaneous tissue disorders Rash	8.0% 2/25 • Number of events 2 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	8.3% 2/24 • Number of events 2 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	4.5% 1/22 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/26 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	8.7% 2/23 • Number of events 2 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
Skin and subcutaneous tissue disorders Rash Erythematous	8.0% 2/25 • Number of events 2 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/24 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/22 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/26 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/23 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
Skin and subcutaneous tissue disorders Urticaria	4.0% 1/25 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/24 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	9.1% 2/22 • Number of events 2 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	3.8% 1/26 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	4.3% 1/23 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
Vascular disorders Angiopathy	0.00% 0/25 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/24 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	9.1% 2/22 • Number of events 2 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/26 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	0.00% 0/23 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.
Vascular disorders Hypertension	8.0% 2/25 • Number of events 2 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	8.3% 2/24 • Number of events 2 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	22.7% 5/22 • Number of events 6 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	3.8% 1/26 • Number of events 1 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.	8.7% 2/23 • Number of events 2 • Up to Day 121 As this was a safety study of Vorapaxar in a clinical setting administered concomitantly with other antiplatelet agents, safety data were collected for all 120 enrolled participants on study, regardless of treatment with study drug.

Additional Information

Senior Vice President, Global Clinical Development

Merck Sharp & Dohme Corp

Phone: 1-800-672-6372

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee Prior approval by the Sponsor is required before the results obtained in the clinical study can be made public by the investigator (sub-investigator) in a publication or at a medical meeting.
Publication restrictions are in place

Restriction type: OTHER